Optune Lua: The Newest Advancement in Tumor Treating Fields Technology for Malignant Pleural Mesothelioma
In May, Optune Lua became the first FDA-approved Tumor Treating Fields device designed for use with standard dual-drug chemotherapy for patients diagnosed with inoperable malignant pleural mesothelioma. Previously named the NovoTTF-100L System, the portable device was created by Novocure, a global oncology company leading the way in new therapies for solid tumors. Optune Lua is […]